Lewis Brisbois-Repped Cancer Biotech Plans $25M IPO
Oncology biotechnology and machine-learning research group Lantern Pharma Inc. on Tuesday set the price range for its planned $25 million initial public offering, guided by Lewis Brisbois Bisgaard & Smith LLP....To view the full article, register now.
Already a subscriber? Click here to view full article